Delineation of rat kidney α2A- and α2B-adrenoeeptors with [3H]RX821002 radiollgand binding: computer modelling reveals that guanfacine is an α2A-selective compound
Abstract
We developed a method for the simultaneous determination of drug affinity constants for rat alpha 2A- and alpha 2B-adrenoceptor subtypes by using [3H]RX821002 radioligand binding in the kidney. Three competition curves were obtained for each drug: one for the test compound in the absence of ARC 239 (a drug found to have 108-fold higher affinity for alpha 2B- than for alpha 2A-adrenoceptors), one in the presence of ARC 239, and one for ARC 239. It is possible to determine the Kds of a tested drug for both alpha 2A- and alpha 2B-adrenoceptors by simultaneous computer modelling because of the increased constraint in the calculations given by the inclusion of ARC 239 into the assay. Using this approach, we found guanfacine and oxymetazoline to be highly alpha 2A-selective. The most alpha 2B-selective were ARC 239, prazosin and corynanthine. A number of other drugs, for example UK-14,304, rilmenidine and clonidine, were non-selective or showed minor selectivity for alpha 2A- or alpha 2B-adrenoceptors. Moreover, using Monte Carlo simulations, we showed that the three-curve method gives more accurate estimates of drug binding constants for assays when two receptor sites are present than methods analysing only one competition curve.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Guanfacine is the most selective α2A-adrenoceptor agonist currently available, with higher affinity for the α2A- than for the α2B- or α2C-adrenoceptor subtypes.
“Guanfacine is the most selective α2A-adrenoceptor agonist currently available, with higher affinity for the α2A- than for the α2B- or α2C-adrenoceptor subtypes (Uhlén et al., 1995; Uhlen and Wikberg, 1991)”
From Catecholamine influences on prefrontal cortical function: Relevance to treatment of attention deficit/hyperactivity disorder and related disorders (2011) · cites this paper as Uhlen and Wikberg, 1991
The citation lists haven’t been fetched yet
References 41 · Cited by 141
- Authors
- Uhlén, S., & Wikberg, J. E. S.
- Affiliations
- Umeå University (SE)
- Corresponding author
- Wikberg, Jarl E.S.
- ORCID
- Wikberg, Jarl E.S.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 1991-09
- Volume
- 202
- Issue
- 2
- Pages
- 235-243
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W1973930439
- Cited by
- 141
- References
- 41
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 2 · 2020: 1 · 2016: 4 · 2015: 3 · 2014: 5 · 2013: 3 · 2012: 4
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- alpha2A-adrenoceptor, alpha2B-adrenoceptor, RX821002, receptor subtype selectivity, guanfacine, oxymetazoline, prazosin, corynanthine, rilmenidine, clonidine, UK 14,304, competitive binding assay, Monte Carlo simulation
- MeSH terms
- Animals, Computer Simulation, Dioxanes, Isoquinolines, Kidney, Male, Monte Carlo Method, Piperazines, Radioligand Assay, Rats, Inbred Strains, Receptors, Adrenergic, alpha, Guanfacine, Idazoxan, Rats, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review